To present a corporate progress report, including an update on the Company´s lead product candidate, Cinryze(TM) (C1 inhibitor (human))

Lev Pharmaceuticals Inc. has entered into a letter agreement with the Sanquin Blood Supply Foundation, authorizing the drugmaker to file for European marketing authorization of its lead product candidate, Cinryze (C1 inhibitor [human]), for the treatment of hereditary angioedema, also known as C1 inhibitor deficiency. In addition, Lev has received notification from the European Medicines Agency (EMEA) that it is eligible to submit an application for Cinryze through the centralized European registration procedure. Cinryze is manufactured in Europe by Sanquin using a state-of-the-art nano-filtration purification process under a distribution and manufacturing services agreement with Lev. Under its deal with Sanquin, Lev currently holds the exclusive rights to market and distribute the compound for the treatment of HAE in North America. Lev is presently in discussions with Sanquin to expand its authorized territory to include certain European countries. Sanquin has been manufacturing C1 inhibitor for more than 35 years in Europe to treat patients with the hereditary disease.

To present a corporate progress report, including an update on the Company´s lead product candidate Cinryze(TM) (C1 inhibitor (human))